SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

AGM Statement

30 Jun 2005 09:43

SR Pharma plcAnnual General Meeting StatementLondon 30 June 2005 - SR Pharma plc ("the Company") announces that at theAnnual General Meeting of the Company held earlier today, all resolutions werepassed.The passing of Resolutions 6 & 7 has given the Directors authority toissue Ordinary Shares up to an aggregate nominal amount of ‚£1,000,000, whichwill enable the Directors to complete the acquisition of Atugen AG, subject toshareholder approval at the Extraordinary General Meeting scheduled for 11 July2005, as set out in the Company circular to shareholders that was posted andannounced on 24 June 2005 and to undertake the fundraising that was describedin the same circular.Further informationMelvyn DaviesCompany SecretarySR Pharma plcTel: 020 7307 1620ENDSR PHARMA PLC
Date   Source Headline
17th May 20115:39 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
16th May 20113:36 pmPRNGrant of options and warrants
16th May 20112:30 pmPRNResult of General Meeting
16th May 20117:00 amPRNResults of Placing and Open Offer
12th May 20115:42 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
27th Apr 20117:06 amPRNPlacing and Open Offer of New Ordinary Shares
27th Apr 20117:01 amPRNFull Year Results for the Year Ended 31 December 2010
26th Apr 20114:40 pmRNSSecond Price Monitoring Extn
26th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20114:40 pmRNSSecond Price Monitoring Extn
7th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20111:37 pmRNSTR-1: Notification of Major Interest in Shares
4th Apr 20114:40 pmRNSSecond Price Monitoring Extn
4th Apr 20114:35 pmRNSPrice Monitoring Extension
21st Mar 20118:00 amRNSPF-04523655 Phase 2 Study Results
14th Feb 20114:35 pmRNSPrice Monitoring Extension
7th Feb 20117:00 amRNSOffer Update
21st Dec 20107:00 amRNSYear-end Update
17th Nov 20104:40 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
16th Nov 20104:40 pmRNSSecond Price Monitoring Extn
16th Nov 20104:35 pmRNSPrice Monitoring Extension
15th Nov 20104:40 pmRNSSecond Price Monitoring Extn
15th Nov 20104:35 pmRNSPrice Monitoring Extension
12th Nov 20102:53 pmPRNForm 8.3 - Silence Therapeutics Plc
12th Nov 20101:35 pmBUSForm 8.3 - Silence Therapeutics plc
11th Nov 20101:54 pmPRNForm 8.3 - Silence Therapeutics Plc
11th Nov 201011:49 amRNSHolding in Company
11th Nov 20107:28 amBUSForm 8.3 - Silence Therapeutics plc
5th Nov 20104:40 pmRNSSecond Price Monitoring Extn
5th Nov 20104:35 pmRNSPrice Monitoring Extension
22nd Oct 20107:53 amBUSForm 8.3 - Silence Therapeutics plc
21st Oct 20109:23 amBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20103:35 pmBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20107:00 amRNSSilence Therapeutics Receives European RNAi Patent
19th Oct 20101:21 pmBUSForm 8.3 - Silence Therapeutics plc
18th Oct 20104:40 pmRNSSecond Price Monitoring Extn
18th Oct 20104:35 pmRNSPrice Monitoring Extension
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20102:28 pmBUSForm 8.3 - Silence Therapeutics plc
15th Oct 20101:52 pmBUSForm 8.3 - Silence Therapeutics plc
12th Oct 20104:35 pmRNSPrice Monitoring Extension
11th Oct 20105:04 pmBUSForm 8.3 - Silence Therapeutics plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.